DIEGO SALAS: Open Payments
NPI 1386372654 · VISTA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$344 in 17 payments from 11 companies in 2025. Trend: 2023 $16 · 2024 $14 · 2025 $344
Food & beverage: $344
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 4 | $69 |
| Gilead Sciences, Inc. | 2 | $61 |
| E.R. Squibb & Sons, L.L.C. | 2 | $41 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $31 |
| Novo Nordisk Inc | 1 | $24 |
| GlaxoSmithKline, LLC. | 1 | $22 |
| Cranial Technologies, Inc | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| Hologic Sales and Service, LLC | 1 | $18 |
Products named: JARDIANCE, COBENFY, MOUNJARO, Wegovy, SHINGRIX, ZEPBOUND, Doc Band, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
